Inclusion Criteria:

          -  History of histologically confirmed colorectal adenocarcinoma metastatic to the liver
             with no clinical or radiographic evidence of extrahepatic disease. Confirmation of
             diagnosis must be performed at MSKCC.

          -  Completely resected hepatic metastases without current evidence of other metastatic
             disease.

          -  Lab values ≤ 14 days prior to treatment start:

          -  WBC ≥ 3.0 K/uL

          -  ANC > 1.5 K/uL

          -  Platelets ≥ 100,000/uL

          -  Creatinine <1.5 mg/dL

          -  HGB ≥ 9 gm/dL Renal function (≤ 14 days prior to treatment start).

          -  Creatinine ≤1.5 mg/dL or creatinine clearance ≥ 50 mL/min calculated by the

        Cockcroft-Gault method as follows:

          -  Male creatinine clearance = (140 -age in years) x (weight in Kg) / (serum Cr in mg/dl
             x 72)

          -  Female creatinine clearance = (140 - age in years) x (weight in Kg) x 0.85 / (serum Cr
             in mg/dl x 72) (use of creatinine clearance per protocol based on chemotherapy
             regimen) Hepatic function, as follows: (≤ 14 days prior to treatment start)

          -  Aspartate aminotransferase (AST) (≤ 5 x ULN)

          -  Alanine aminotransferase (ALT) (≤ 5 x ULN)

          -  Total Bilirubin ≤ 1.5 mg/dl

          -  Magnesium ≥ lower limit of normal (≤ 48 hours prior to treatment start.)

          -  Calcium ≥ lower limit of normal (≤ 48 hours prior to treatment start.)

          -  Prior chemotherapy is acceptable if last dose given ≥ 3 weeks prior to registration to
             this study. [Note: no chemotherapy to be given after resection of liver lesions prior
             to treatment on this study.]

          -  Any investigational agent is acceptable if administered ≤ 30 days before registration

          -  KPS ≥ 60% (ECOG (or Karnofsky) performance status (preferably 0 or 1/≥ 60% for
             Karnofsky)

          -  Histologically confirmed all RAS wild type.

          -  Paraffin-embedded tumor tissue obtained from the primary tumor or metastasis (Prior to

        Exclusion Criteria:

          -  Patients < 18 years of age.

          -  Prior radiation to the liver (Prior radiation therapy to the pelvis is acceptable if
             completed at least 4 weeks prior to registration.)

          -  Active infection, ascites, hepatic encephalopathy.

          -  Prior treatment with HAI FUDR.

          -  Patients who have had prior anti EGFR antibody therapy inhibitors and who have not
             responded to this treatment will be excluded. However, patients who have responded to
             prior anti-EGFR therapy are eligible.)

          -  Female patients who are pregnant or lactating - or planning to become pregnant within
             6 months after the end of the treatment (female patients of child-bearing potential
             must have negative pregnancy test ≤ 72 hours before registration).

          -  If a patient has any serious medical problems which may preclude receiving this type
             of treatment.

          -  Patients with current evidence of hepatitis A, B, C (ie, active hepatitis)

          -  Patients with history or known presence of primary CNS tumors, seizures not well
             controlled with standard medical therapy, or history of stroke will also be excluded.

          -  History of allergic reactions attributed to compounds of similar chemical or biologic
             composition to Panitumumab.

          -  Serious or non-healing active wound, ulcer, or bone fracture.

          -  History of interstitial lung disease e.g. pneumonitis or pulmonary fibrosis or
             evidence of interstitial lung disease on baseline chest CT scan.

          -  Patients who have a diagnosis of Gilbert's disease.

          -  History of other malignancy, except:

          -  Malignancy treated with curative intent and with no known active disease present for ≥
             3 years prior to registration and felt to be at low risk for recurrence by the
             treating physician

          -  Adequately treated non-melanomatous skin cancer or lentigo maligna without evidence of
             disease

          -  Adequately treated cervical carcinoma in situ without evidence of disease